Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30% of patients develop resistance to the therapy. To improve the outcomes, identification of new targets o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitrovský, Ondřej, Myslivcová, Denisa, Macháčková-Lopotová, Tereza, Obr, Adam, Čermáková, Kamila, Ransdorfová, Šárka, Březinová, Jana, Klamová, Hana, Žáčková, Markéta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159124/
https://www.ncbi.nlm.nih.gov/pubmed/37141212
http://dx.doi.org/10.1371/journal.pone.0284876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159124/
https://www.ncbi.nlm.nih.gov/pubmed/37141212
http://dx.doi.org/10.1371/journal.pone.0284876

Ejemplares similares